• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More or Call (407) 374-6986

Monday 12/10/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Mino-Lok

  • 2:04 PM

    Worldwide License for Mino-Lok™ is Now Complete CRANFORD, N.J., March 23, 2017, CTXR, /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius”) (OTC BB: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that it has recently concluded negotiations to add South America to its worldwide license for Mino-Lok™.  South America was the only territory that was not included in the original sub-license between Novel Anti-Infective Technologies, LLC, an affiliate of MD Anderson Cancer Center (“MDACC”), and

    Read more
  • 3:09 PM

    Manufacturing Finalized and Site Recruitment Initiated PR Newswire, CTXR CRANFORD, N.J., Dec. 8, 2016 CRANFORD, N.J., Dec. 8, 2016 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius”) (OTC BB: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, provided details of its phase 3 trial for Mino-Lok™, an antibiotic lock solution used to salvage infected central venous catheters (CVCs) and to treat catheter related bloodstream infections (CRBSIs).  Mino-Lok is being developed as an adjunctive therapy for the treatment of

    Read more
  • 7:26 PM

    Two Contract Manufacturing Organizations Engaged to Produce Clinical Trial Material PR Newswire CRANFORD, N.J., Sept. 8, 2016 CRANFORD, N.J., Sept. 8, 2016, CTXR, /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius”) (OTC QB: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that it has initiated manufacturing for the company’s clinical trial of Mino-Lok ™, an antibiotic lock solution used to salvage central venous catheters (CVCs) and to treat catheter related bloodstream infections (CRBSIs).

    Read more
  • 4:27 PM

    Long-term agreement with Mosaic Energy Ltd. underpins $170 million gas plant expansion and associated new gathering pipeline CALGARY, Oct. 10, 2014 /PRNewswire/ – Pembina Pipeline Corporation (“Pembina” or the “Company”) (TSX: PPL; NYSE: PBA) announced today that it has entered into commercial agreements to proceed with a $170 million expansion of the Company’s recently completed Resthaven Facility (a 200 million cubic feet per day (“MMcf/d”) (134 MMcf/d net to Pembina) gas processing facility) and to build, own and operate a new gas

    Read more
Public Wire Banner